Literature DB >> 21097698

Expression of PD-L1 and PD-L2 on human macrophages is up-regulated by HIV-1 and differentially modulated by IL-10.

Marta Rodríguez-García1, Filippos Porichis, Olivier G de Jong, Karen Levi, Thomas J Diefenbach, Jeffrey D Lifson, Gordon J Freeman, Bruce D Walker, Daniel E Kaufmann, Daniel G Kavanagh.   

Abstract

PD-1 plays an important role in T cell exhaustion during HIV infection. PD-1 has two ligands: PD-L1, expressed on hematopoietic and nonhematopoietic cells, and PD-L2, limited to DCs and macrophages. Little is known about PD-L1 expression and regulation in human macrophages. Previous reports have found few immediate effects of macrophage exposure to HIV, suggesting that macrophages lack PRRs for this virus. Using quantitative confocal microscopy and a multiplexed cytokine bead array, we measured induction of PD-L1, PD-L2, and innate response cytokines in human MDMs in response to chemically inactivated HIV virions. Consistent with previous reports, no cytokines were induced by HIV virion exposure. Whereas PD-L1 and PD-L2 had low baseline expression, TLR ligands (LPS and CL097) up-regulated PD-L1 but not PD-L2. Unlike what we found for cytokine expression, PD-L1 and PD-L2 were up-regulated in response to exposure with inactivated HIV virions or with replication-competent HIV. Expression of PD-L1 was differentially modulated by IL-10, which induced up-regulation of PD-L1 but not of PD-L2, and IL-10 blockade enhanced only PD-L2 expression. We discuss implications for innate recognition of HIV by macrophages and potential, different roles for PD-L1 and PD-L2 in immunity and pathogenesis.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21097698      PMCID: PMC3058820          DOI: 10.1189/jlb.0610327

Source DB:  PubMed          Journal:  J Leukoc Biol        ISSN: 0741-5400            Impact factor:   4.962


  40 in total

1.  PD-L1 and PD-L2 are differentially regulated by Th1 and Th2 cells.

Authors:  P'ng Loke; James P Allison
Journal:  Proc Natl Acad Sci U S A       Date:  2003-04-15       Impact factor: 11.205

2.  Upregulation of PD-L1 on monocytes and dendritic cells by HIV-1 derived TLR ligands.

Authors:  Angela Meier; Aranya Bagchi; Harlyn K Sidhu; Galit Alter; Todd J Suscovich; Daniel G Kavanagh; Hendrik Streeck; Mark A Brockman; Sylvie LeGall; Judith Hellman; Marcus Altfeld
Journal:  AIDS       Date:  2008-03-12       Impact factor: 4.177

3.  Programmed death-1-induced interleukin-10 production by monocytes impairs CD4+ T cell activation during HIV infection.

Authors:  Elias A Said; Franck P Dupuy; Lydie Trautmann; Yuwei Zhang; Yu Shi; Mohamed El-Far; Brenna J Hill; Alessandra Noto; Petronela Ancuta; Yoav Peretz; Simone G Fonseca; Julien Van Grevenynghe; Mohamed R Boulassel; Julie Bruneau; Naglaa H Shoukry; Jean-Pierre Routy; Daniel C Douek; Elias K Haddad; Rafick-Pierre Sekaly
Journal:  Nat Med       Date:  2010-03-07       Impact factor: 53.440

4.  The role of mononuclear phagocytes in HTLV-III/LAV infection.

Authors:  S Gartner; P Markovits; D M Markovitz; M H Kaplan; R C Gallo; M Popovic
Journal:  Science       Date:  1986-07-11       Impact factor: 47.728

Review 5.  The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection.

Authors:  Arlene H Sharpe; E John Wherry; Rafi Ahmed; Gordon J Freeman
Journal:  Nat Immunol       Date:  2007-03       Impact factor: 25.606

6.  Microvesicles are a source of contaminating cellular proteins found in purified HIV-1 preparations.

Authors:  J W Bess; R J Gorelick; W J Bosche; L E Henderson; L O Arthur
Journal:  Virology       Date:  1997-03-31       Impact factor: 3.616

Review 7.  Immune tolerance: what is unique about the liver.

Authors:  Gisa Tiegs; Ansgar W Lohse
Journal:  J Autoimmun       Date:  2009-08-29       Impact factor: 7.094

8.  PD-1 inhibits antiviral immunity at the effector phase in the liver.

Authors:  Yoshiko Iwai; Seigo Terawaki; Masaya Ikegawa; Taku Okazaki; Tasuku Honjo
Journal:  J Exp Med       Date:  2003-07-07       Impact factor: 14.307

9.  B7DC/PDL2 promotes tumor immunity by a PD-1-independent mechanism.

Authors:  Xingluo Liu; Jian Xin Gao; Jing Wen; Lijie Yin; Ou Li; Tao Zuo; Thomas F Gajewski; Yang-Xin Fu; Pan Zheng; Yang Liu
Journal:  J Exp Med       Date:  2003-06-16       Impact factor: 14.307

10.  Macrophage deactivation by interleukin 10.

Authors:  C Bogdan; Y Vodovotz; C Nathan
Journal:  J Exp Med       Date:  1991-12-01       Impact factor: 14.307

View more
  62 in total

Review 1.  PD-1 immunobiology in systemic lupus erythematosus.

Authors:  Colleen S Curran; Sarthak Gupta; Ignacio Sanz; Elad Sharon
Journal:  J Autoimmun       Date:  2018-11-03       Impact factor: 7.094

2.  Spatial alterations between CD4(+) T follicular helper, B, and CD8(+) T cells during simian immunodeficiency virus infection: T/B cell homeostasis, activation, and potential mechanism for viral escape.

Authors:  Jung Joo Hong; Praveen K Amancha; Kenneth Rogers; Aftab A Ansari; Francois Villinger
Journal:  J Immunol       Date:  2012-03-02       Impact factor: 5.422

3.  Urban-rural differences in the gene expression profiles of Ghanaian children.

Authors:  A S Amoah; B B Obeng; L May; Y C Kruize; I A Larbi; M Kabesch; M D Wilson; F C Hartgers; D A Boakye; M Yazdanbakhsh
Journal:  Genes Immun       Date:  2014-05-22       Impact factor: 2.676

4.  Menopausal status influences the expression of programmed death (PD)-1 and its ligand PD-L1 on immune cells from the human female reproductive tract.

Authors:  Zheng Shen; Marta Rodriguez-Garcia; Mickey V Patel; Fiona D Barr; Charles R Wira
Journal:  Am J Reprod Immunol       Date:  2016-06-19       Impact factor: 3.886

5.  Differential impact of PD-1 and/or interleukin-10 blockade on HIV-1-specific CD4 T cell and antigen-presenting cell functions.

Authors:  Filippos Porichis; Meghan G Hart; Jennifer Zupkosky; Lucie Barblu; Douglas S Kwon; Ashley McMullen; Thomas Brennan; Rafi Ahmed; Gordon J Freeman; Daniel G Kavanagh; Daniel E Kaufmann
Journal:  J Virol       Date:  2013-12-18       Impact factor: 5.103

6.  CMTM6 stabilizes PD-L1 expression and refines its prognostic value in tumors.

Authors:  Emilie Mamessier; David J Birnbaum; Pascal Finetti; Daniel Birnbaum; François Bertucci
Journal:  Ann Transl Med       Date:  2018-02

7.  Immune targeting of PD-1(hi) expressing cells during and after antiretroviral therapy in SIV-infected rhesus macaques.

Authors:  Diego A Vargas-Inchaustegui; Peng Xiao; Alison E Hogg; Thorsten Demberg; Katherine McKinnon; David Venzon; Egidio Brocca-Cofano; Janet Dipasquale; Eun M Lee; Lauren Hudacik; Ranajit Pal; Yongjun Sui; Jay A Berzofsky; Linda Liu; Solomon Langermann; Marjorie Robert-Guroff
Journal:  Virology       Date:  2013-10-09       Impact factor: 3.616

8.  Blocking immunoinhibitory receptor LILRB2 reprograms tumor-associated myeloid cells and promotes antitumor immunity.

Authors:  Hui-Ming Chen; William van der Touw; Yuan Shuo Wang; Kyeongah Kang; Sunny Mai; Jilu Zhang; Dayanira Alsina-Beauchamp; James A Duty; Sathish Kumar Mungamuri; Bin Zhang; Thomas Moran; Richard Flavell; Stuart Aaronson; Hong-Ming Hu; Hisashi Arase; Suresh Ramanathan; Raja Flores; Ping-Ying Pan; Shu-Hsia Chen
Journal:  J Clin Invest       Date:  2018-10-22       Impact factor: 14.808

9.  Targeting type I interferon-mediated activation restores immune function in chronic HIV infection.

Authors:  Anjie Zhen; Valerie Rezek; Cindy Youn; Brianna Lam; Nelson Chang; Jonathan Rick; Mayra Carrillo; Heather Martin; Saro Kasparian; Philip Syed; Nicholas Rice; David G Brooks; Scott G Kitchen
Journal:  J Clin Invest       Date:  2016-12-12       Impact factor: 14.808

Review 10.  Cytokine production and dysregulation in HIV pathogenesis: lessons for development of therapeutics and vaccines.

Authors:  Morgan A Reuter; Carolina Pombo; Michael R Betts
Journal:  Cytokine Growth Factor Rev       Date:  2012-06-27       Impact factor: 7.638

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.